









Markets
/
Stocks
/
nasdaq-exas
/

Exact Sciences Corp

EXAS

62.880USD

+0.140+0.22%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

11.90BMarket Cap

LossP/E TTM



Exact Sciences Corp

62.880

+0.140+0.22%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Exact Sciences Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exact Sciences Corp's Score

Industry at a Glance

Industry Ranking

11 / 407

Overall Ranking

64 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 24 analysts

Buy

Current Rating

69.815

Target Price

+10.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Exact Sciences Corp Highlights

StrengthsRisks

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.37% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.76B.

Overvalued

The company’s latest PE is -11.53, at a high 3-year percentile range.

Fairly Valued

The company’s latest PE is -11.53, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 181.01M shares, decreasing 9.98% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 52.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.52.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 7.41, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 811.09M, representing a year-over-year increase of 15.99%, while its net profit experienced a year-over-year increase of 92.50%.

Score

Industry at a Glance

Previous score

7.41

Change



Financials

6.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Exact Sciences Corp's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.55, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -11.53, which is -36.68% below the recent high of -7.30 and -542.99% above the recent low of -74.11.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.64, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Exact Sciences Corp is 68.11, with a high of 100.00 and a low of 53.00.

Score

Industry at a Glance

Previous score

8.64

Change

Support & Resistance

No Data

Analyst Rating

Based on 24 analysts

Buy

Current Rating

69.815

Target Price

+10.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

Exact Sciences Corp

EXAS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 66.93 and the support level at 57.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.80

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.140

Neutral

RSI(14)

65.634

Neutral

STOCH(KDJ)(9,3,3)

53.662

Sell

ATR(14)

1.652

Low Volatility

CCI(14)

38.529

Neutral

Williams %R

35.068

Buy

TRIX(12,20)

0.712

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

63.806

Sell

MA10

63.060

Sell

MA20

60.825

Buy

MA50

55.271

Buy

MA100

52.701

Buy

MA200

51.291

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 95.61%, representing a quarter-over-quarter decrease of 10.63%. The largest institutional shareholder is The Vanguard, holding a total of 17.87M shares, representing 9.44% of shares outstanding, with 3.06% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

23.28M

-3.53%

Capital World Investors

18.20M

+2.05%

The Vanguard Group, Inc.

Star Investors

17.87M

+1.73%

Wellington Management Company, LLP

12.00M

-3.98%

BlackRock Institutional Trust Company, N.A.

7.04M

-8.35%

State Street Investment Management (US)

5.38M

-18.67%

MFS Investment Management

2.96M

+97.24%

Fidelity Institutional Asset Management

3.61M

+0.59%

T. Rowe Price Associates, Inc.

Star Investors

3.55M

-43.25%

Geode Capital Management, L.L.C.

3.24M

-0.90%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 6.91, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.